ProRx LLC – FDA Warning Letter, Sep 19, 2025

On April 7, 2026, the FDA issued a warning letter to ProRx LLC following an inspection of its Exton, Pennsylvania facility conducted from September 9 to September 19, 2025. The agency determined that the firm failed to meet the necessary conditions to qualify as an outsourcing facility under Section 503B of the Federal Food, Drug, and Cosmetic Act. Key violations included compounding drugs such as Tirzepatide using bulk substances not included on the approved 503B list or the official drug shortage list. The FDA also identified serious sanitary deficiencies that put patient safety at risk, including microbial contamination in sterile production areas, improper aseptic techniques by personnel, and inadequate disinfection of materials. Furthermore, the facility lacked sufficient quality controls, failing to thoroughly investigate manufacturing discrepancies or maintain adequate environmental monitoring systems. These issues led to the production of drugs deemed adulterated and misbranded. ProRx LLC is required to submit a written response within 15 working days outlining specific corrective actions and a timeline for implementation. The FDA strongly recommends that the company engage a third-party consultant with expertise in sterile drug manufacturing to perform a comprehensive audit of their operations, facility design, and quality systems to ensure full compliance with federal safety standards.